DK1471871T3 - Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin - Google Patents
Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietinInfo
- Publication number
- DK1471871T3 DK1471871T3 DK02724904T DK02724904T DK1471871T3 DK 1471871 T3 DK1471871 T3 DK 1471871T3 DK 02724904 T DK02724904 T DK 02724904T DK 02724904 T DK02724904 T DK 02724904T DK 1471871 T3 DK1471871 T3 DK 1471871T3
- Authority
- DK
- Denmark
- Prior art keywords
- erythropoietin
- treatment
- neurological dysfunction
- dysfunction including
- fructopyranose sulfamates
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title abstract 2
- 108090000394 Erythropoietin Proteins 0.000 title abstract 2
- 229940105423 erythropoietin Drugs 0.000 title abstract 2
- -1 fructopyranose sulfamates Chemical class 0.000 title abstract 2
- 230000009251 neurologic dysfunction Effects 0.000 title abstract 2
- 208000015015 neurological dysfunction Diseases 0.000 title abstract 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011262 co‐therapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26619401P | 2001-02-02 | 2001-02-02 | |
| PCT/US2002/003096 WO2002064085A2 (fr) | 2001-02-02 | 2002-01-24 | Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1471871T3 true DK1471871T3 (da) | 2007-09-17 |
Family
ID=23013568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02724904T DK1471871T3 (da) | 2001-02-02 | 2002-01-24 | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6908902B2 (fr) |
| EP (1) | EP1471871B1 (fr) |
| JP (1) | JP2005501801A (fr) |
| KR (1) | KR100896971B1 (fr) |
| AT (1) | ATE361089T1 (fr) |
| CA (1) | CA2437333A1 (fr) |
| CY (1) | CY1106733T1 (fr) |
| DE (1) | DE60219961T8 (fr) |
| DK (1) | DK1471871T3 (fr) |
| ES (1) | ES2284858T3 (fr) |
| MX (1) | MXPA03006952A (fr) |
| NO (1) | NO20033440L (fr) |
| NZ (1) | NZ548578A (fr) |
| PT (1) | PT1471871E (fr) |
| RU (1) | RU2317086C2 (fr) |
| WO (1) | WO2002064085A2 (fr) |
| ZA (1) | ZA200306818B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| KR100896971B1 (ko) * | 2001-02-02 | 2009-05-14 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법 |
| US20030060423A1 (en) * | 2001-08-30 | 2003-03-27 | Plata-Salaman Carlos R. | Co-therapy for the treatment of dementia and associated behavioral manifestations comprising anticonvulsant derivatives and acetylcholinesterase inhibitors |
| JP2005534650A (ja) * | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| US20030235576A1 (en) * | 2002-06-15 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New drug combinations for the treatment of ischaemic conditions |
| DE10226814A1 (de) * | 2002-06-15 | 2004-01-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände |
| EP1815854A1 (fr) * | 2002-09-17 | 2007-08-08 | Motac Neuroscience Limited | Traitement de dyskinésie |
| ES2286453T3 (es) * | 2002-09-17 | 2007-12-01 | Motac Neuroscience Limited | Tratamiento de la discinesia. |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| AT500929B1 (de) | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
| WO2007020922A1 (fr) * | 2005-08-17 | 2007-02-22 | Chugai Seiyaku Kabushiki Kaisha | Traitement et prévention de maladies cérébrales |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| WO2008022349A2 (fr) * | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents pour barrière hémato-encéphalique |
| WO2008088820A2 (fr) * | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Antagonistes de récepteur de glutamate et procédés d'utilisation |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| RU2335296C1 (ru) * | 2007-06-26 | 2008-10-10 | Сергей Марович Дудкин | Фармацевтическая композиция для профилактики и лечения неврологических заболеваний |
| CA2694762A1 (fr) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Procedes et compositions destines a augmenter une activite a-iduronidase dans le snc |
| CA2724841A1 (fr) * | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Traitement de maladies mitochondriales par un mimetique d'erythropoietine |
| US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| EP2408474B1 (fr) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions et procédés pour le transport de protéines de fusion igg-récepteur leurre à travers la barrière hémato-encéphalique |
| HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
| ES2983576T3 (es) | 2011-12-02 | 2024-10-23 | Armagen Inc | Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC |
| US9457008B2 (en) | 2012-03-23 | 2016-10-04 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China | Joint product comprising synephrine and topiramate |
| CN102579367B (zh) | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| DK173067B1 (da) | 1986-06-27 | 1999-12-13 | Univ Washington | Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa |
| US5242942A (en) | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5384327A (en) | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| JPH09501418A (ja) | 1993-07-19 | 1997-02-10 | アムジエン・インコーポレーテツド | エアゾル化タンパク質の安定化 |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5773569A (en) | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
| DE69434652T2 (de) * | 1993-12-23 | 2007-03-01 | Ortho-Mcneil Pharmaceutical, Inc. | Antikonvulsive pseudofructopyranose sulfamate |
| IL116085A (en) | 1994-12-16 | 1999-12-31 | Ortho Pharma Corp | Spray dried erythropoietin |
| US5767078A (en) | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
| US5753694A (en) | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| WO1998000124A1 (fr) | 1996-06-28 | 1998-01-08 | Ortho Pharmaceutical Corporation | Utilisation du topiramate ou de ses derives pour fabriquer un medicament qui traite les affections neurodegeneratives post-ischemiques |
| DE69736780T2 (de) | 1996-08-02 | 2007-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| ATE341625T1 (de) | 1997-07-23 | 2006-10-15 | Roche Diagnostics Gmbh | Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren |
| PT902085E (pt) | 1997-09-01 | 2004-02-27 | Aventis Pharma Gmbh | Eritropoietina humana recombinante com perfil de glicosilacao vantajoso |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| AU759467B2 (en) * | 1998-04-02 | 2003-04-17 | Avicena Group, Inc. | Compositions containing a combination of a creatine compound and a second agent |
| AU775422B2 (en) | 1998-06-15 | 2004-07-29 | Gtc Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion |
| JP2003521471A (ja) * | 1999-04-08 | 2003-07-15 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体 |
| PL352223A1 (en) * | 1999-04-13 | 2003-08-11 | Kenneth S Warren Inst | Modulation of excitable tissue function by peripherally administered erythropoietin |
| CA2270795A1 (fr) * | 1999-05-05 | 2000-11-05 | Gestilab Inc. | Compositions neuroprotectrices et utilisations de ces compositions |
| KR100896971B1 (ko) * | 2001-02-02 | 2009-05-14 | 오르토-맥네일 파마슈티칼, 인코퍼레이티드 | 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법 |
-
2002
- 2002-01-24 KR KR1020037010232A patent/KR100896971B1/ko not_active Expired - Fee Related
- 2002-01-24 JP JP2002563882A patent/JP2005501801A/ja not_active Ceased
- 2002-01-24 RU RU2003124059/14A patent/RU2317086C2/ru not_active IP Right Cessation
- 2002-01-24 DK DK02724904T patent/DK1471871T3/da active
- 2002-01-24 US US10/056,828 patent/US6908902B2/en not_active Expired - Lifetime
- 2002-01-24 CA CA002437333A patent/CA2437333A1/fr not_active Abandoned
- 2002-01-24 ES ES02724904T patent/ES2284858T3/es not_active Expired - Lifetime
- 2002-01-24 WO PCT/US2002/003096 patent/WO2002064085A2/fr not_active Ceased
- 2002-01-24 AT AT02724904T patent/ATE361089T1/de active
- 2002-01-24 NZ NZ548578A patent/NZ548578A/en not_active IP Right Cessation
- 2002-01-24 PT PT02724904T patent/PT1471871E/pt unknown
- 2002-01-24 DE DE60219961T patent/DE60219961T8/de active Active
- 2002-01-24 EP EP02724904A patent/EP1471871B1/fr not_active Expired - Lifetime
- 2002-01-24 MX MXPA03006952A patent/MXPA03006952A/es active IP Right Grant
-
2003
- 2003-08-01 NO NO20033440A patent/NO20033440L/no not_active Application Discontinuation
- 2003-09-01 ZA ZA2003/06818A patent/ZA200306818B/en unknown
-
2005
- 2005-01-31 US US11/047,420 patent/US20050261182A1/en not_active Abandoned
-
2007
- 2007-07-13 CY CY20071100943T patent/CY1106733T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002064085A3 (fr) | 2004-09-10 |
| DE60219961T2 (de) | 2008-01-17 |
| CA2437333A1 (fr) | 2002-08-22 |
| KR100896971B1 (ko) | 2009-05-14 |
| CY1106733T1 (el) | 2012-05-23 |
| KR20040011458A (ko) | 2004-02-05 |
| JP2005501801A (ja) | 2005-01-20 |
| RU2003124059A (ru) | 2005-01-27 |
| ZA200306818B (en) | 2005-02-23 |
| DE60219961T8 (de) | 2008-04-17 |
| EP1471871B1 (fr) | 2007-05-02 |
| NZ548578A (en) | 2008-03-28 |
| EP1471871A4 (fr) | 2005-11-09 |
| PT1471871E (pt) | 2007-06-05 |
| US6908902B2 (en) | 2005-06-21 |
| DE60219961D1 (de) | 2007-06-14 |
| ES2284858T3 (es) | 2007-11-16 |
| RU2317086C2 (ru) | 2008-02-20 |
| ATE361089T1 (de) | 2007-05-15 |
| NO20033440L (no) | 2003-09-29 |
| MXPA03006952A (es) | 2004-10-15 |
| EP1471871A2 (fr) | 2004-11-03 |
| US20020169109A1 (en) | 2002-11-14 |
| WO2002064085A2 (fr) | 2002-08-22 |
| NO20033440D0 (no) | 2003-08-01 |
| US20050261182A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1471871T3 (da) | Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin | |
| MX231981B (es) | Tratamiento de semillas con combinaciones de piretrinas/piretroides y clotianidina. | |
| MX237325B (es) | Tratamiento para semilla con combinaciones de insecticidas | |
| DK1539166T3 (da) | Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme | |
| DK1047428T3 (da) | Anvendelse af morpholinol til behandlingen af seksualforstyrrelser | |
| DK1392292T3 (da) | Pyranoindazoler og deres anvendelse til behandling af glaukom | |
| GB2394826A (en) | Educational game | |
| ITBO20000453A0 (it) | Apparecchiatura e procedimento per la sterilizzazione del terreno . | |
| DE60200302D1 (de) | Laseraugenbehandlungseinrichtung | |
| DK1143917T3 (da) | Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom | |
| NO20023944L (no) | Blanding og metoder for behandling av epilepsi | |
| IS6619A (is) | S-metýl-díhýdró-siprasídón til meðhöndlunar á geðrænum kvillum og augnkvillum | |
| ATE333439T1 (de) | Pflanzenkläranlage | |
| BR0103928B1 (pt) | equipamento para tratamento de efluentes e estação para tratamento de efluentes. | |
| ITRM20020308A1 (it) | Apparecchiatura per trattamenti terapeutici, e relativo metodo. | |
| DK1500395T3 (da) | Reboxetin til behandling af fibromyalgi og andre somatoforme lidelser | |
| FIU20010133U0 (fi) | Jäteveden käsittelylaitteisto | |
| DK1453783T3 (da) | Substituerede arylcycloalkaner og deres anvendelse som anticancermidler | |
| ATE374611T1 (de) | Antitumor wirksame 2-alkoxyestradiolsulfamate | |
| DE10157913B4 (de) | Therapietisch | |
| FR2825913B1 (fr) | Stimulateur central hydro-dynamogene des membres inferieurs | |
| DK1274700T3 (da) | Dihydrobenzopyraner, dihydrobenzothiopyraner og tetrahydroquinoliner til behandling af COX-2-medierede lidelser | |
| FI5282U1 (fi) | Jäteveden puhdistamo | |
| ES1050173Y (es) | Medalla con calendario perfeccionada. | |
| ES1039627Y (es) | Juego educativo de sobremesa. |